PrEP uptake and delivery setting preferences among clients visiting six healthcare facilities in Eswatini.


Journal

AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133

Informations de publication

Date de publication:
Oct 2022
Historique:
accepted: 01 03 2022
pubmed: 17 4 2022
medline: 17 9 2022
entrez: 16 4 2022
Statut: ppublish

Résumé

Due to the high HIV incidence among the general population of Eswatini, pre-exposure prophylaxis (PrEP) for HIV-exposed individuals is recommended. However, little is known about PrEP uptake and preferences in PrEP delivery healthcare setting among the general population. We conducted a secondary analysis of a randomized trial that aimed to increase PrEP uptake. All clients eligible for PrEP in one of six public-sector healthcare facilities in Eswatini were included. PrEP uptake was stratified by initial reason for visit (e.g. outpatient). Preferences in PrEP delivery setting were collected among those clients who initiated PrEP. A total of 1782 clients had their HIV acquisition risk assessed. Of these, 72% (1277/1782) were considered at risk by healthcare providers and, among them, 40% (517/1277) initiated PrEP. Uptake was higher among clients visiting specifically to initiate PrEP (93%), followed by HIV testing visits (45.8%) and outpatient visits (40%). Among those who initiated PrEP, preferred delivery settings were outpatient services (31%), HIV testing services (26%), family planning (21%) and antenatal services (14%). Men or those at high risk of HIV acquisition were more likely to prefer HIV testing and outpatient services, while young women were more likely to visit and express a preference for antenatal and family planning services. Outpatient services and HIV testing services could be preferable choices for PrEP delivery integration, due to the high PrEP uptake and delivery setting preferences of the populations who use these services. Antenatal and family planning could also be considered with a view to targeting the youngest women. Debido a la alta incidencia del VIH entre la población general de Eswatini, se recomienda la profilaxis previa a la exposición (PrEP) para las personas expuestas al VIH. Sin embargo, se sabe poco sobre la aceptación de la PrEP y las preferencias en el ámbito de la atención sanitaria de la PrEP entre la población general. Se realizó un análisis secundario de un ensayo clínico que pretendía aumentar la aceptación de la PrEP. Se incluyó a todos los clientes elegibles para la PrEP en uno de los seis centros sanitarios del sector público de Eswatini. La aceptación de la PrEP se estratificó según el motivo inicial de la visita (por ejemplo, paciente externo). Se recogieron las preferencias en el entorno de administración de la PrEP entre aquellos clientes que iniciaron la PrEP. Se evaluó el riesgo de adquisición del VIH de un total de 1.782 clientes (de 2.238 contactados, el 80%). De ellos, el 72% (1277/1782) fueron considerados de riesgo por los profesionales sanitarios y, entre ellos, el 40% (517/1277) iniciaron la PrEP. El consumo fue mayor entre los clientes que acudieron específicamente para iniciar la PrEP (93%), seguido de las visitas para realizar la prueba del VIH (45,8%) y las visitas ambulatorias (40%). Entre los que iniciaron la PrEP, los entornos de prestación preferidos fueron los servicios ambulatorios (31%), los servicios de pruebas del VIH (26%), la planificación familiar (21%) y los servicios prenatales (14%). Los hombres o las personas con alto riesgo de contraer el VIH tenían más probabilidades de preferir las pruebas del VIH y los servicios ambulatorios, mientras que las mujeres jóvenes tenían más probabilidades de acudir a los servicios prenatales y de planificación familiar y expresar su preferencia por ellos. Los servicios ambulatorios y los servicios de pruebas del VIH podrían ser opciones preferibles para la integración de la entrega de la PrEP, debido a la alta aceptación de la PrEP y a las preferencias del entorno de entrega de las poblaciones que utilizan estos servicios. Los servicios prenatales y de planificación familiar también podrían considerarse con vistas a dirigirse a las mujeres más jóvenes.

Autres résumés

Type: Publisher (spa)
Debido a la alta incidencia del VIH entre la población general de Eswatini, se recomienda la profilaxis previa a la exposición (PrEP) para las personas expuestas al VIH. Sin embargo, se sabe poco sobre la aceptación de la PrEP y las preferencias en el ámbito de la atención sanitaria de la PrEP entre la población general. Se realizó un análisis secundario de un ensayo clínico que pretendía aumentar la aceptación de la PrEP. Se incluyó a todos los clientes elegibles para la PrEP en uno de los seis centros sanitarios del sector público de Eswatini. La aceptación de la PrEP se estratificó según el motivo inicial de la visita (por ejemplo, paciente externo). Se recogieron las preferencias en el entorno de administración de la PrEP entre aquellos clientes que iniciaron la PrEP. Se evaluó el riesgo de adquisición del VIH de un total de 1.782 clientes (de 2.238 contactados, el 80%). De ellos, el 72% (1277/1782) fueron considerados de riesgo por los profesionales sanitarios y, entre ellos, el 40% (517/1277) iniciaron la PrEP. El consumo fue mayor entre los clientes que acudieron específicamente para iniciar la PrEP (93%), seguido de las visitas para realizar la prueba del VIH (45,8%) y las visitas ambulatorias (40%). Entre los que iniciaron la PrEP, los entornos de prestación preferidos fueron los servicios ambulatorios (31%), los servicios de pruebas del VIH (26%), la planificación familiar (21%) y los servicios prenatales (14%). Los hombres o las personas con alto riesgo de contraer el VIH tenían más probabilidades de preferir las pruebas del VIH y los servicios ambulatorios, mientras que las mujeres jóvenes tenían más probabilidades de acudir a los servicios prenatales y de planificación familiar y expresar su preferencia por ellos. Los servicios ambulatorios y los servicios de pruebas del VIH podrían ser opciones preferibles para la integración de la entrega de la PrEP, debido a la alta aceptación de la PrEP y a las preferencias del entorno de entrega de las poblaciones que utilizan estos servicios. Los servicios prenatales y de planificación familiar también podrían considerarse con vistas a dirigirse a las mujeres más jóvenes.

Identifiants

pubmed: 35429309
doi: 10.1007/s10461-022-03646-0
pii: 10.1007/s10461-022-03646-0
pmc: PMC9474345
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

3345-3355

Subventions

Organisme : NCATS NIH HHS
ID : KL2TR003143
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW009775
Pays : United States
Organisme : FIC NIH HHS
ID : D43-TW009775
Pays : United States
Organisme : World Health Organization
ID : H9/181/R
Pays : International
Organisme : NIA NIH HHS
ID : P01 AG041710
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD084233
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI112339
Pays : United States
Organisme : NIA NIH HHS
ID : P01-AG041710
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR003143
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. The Lancet. 2016;387:53–60. https://doi.org/10.1016/S0140-6736(15)00056-2 .
doi: 10.1016/S0140-6736(15)00056-2
Molina J-M, Capitant C, Spire B, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015;373:2237–46. https://doi.org/10.1056/NEJMoa1506273 .
doi: 10.1056/NEJMoa1506273 pubmed: 26624850
Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2013;381:2083–90. https://doi.org/10.1016/S0140-6736(13)61127-7 .
doi: 10.1016/S0140-6736(13)61127-7
Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423–34. https://doi.org/10.1056/NEJMoa1110711 .
doi: 10.1056/NEJMoa1110711 pubmed: 22784038
WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2016.
AIDS Vaccine Advocacy Coalition (AVAC). The Global Prep Tracker 2000. https://data.prepwatch.org / (accessed January 12, 2021).
UNAIDS. Data. 2020. UNAIDS: Geneva: 2020.
Koechlin FM, Fonner VA, Dalglish SL, et al. Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature. AIDS Behav. 2017;21:1325–35. https://doi.org/10.1007/s10461-016-1627-z .
doi: 10.1007/s10461-016-1627-z pubmed: 27900502
Begnel ER, Escudero J, Mugambi M, et al. High pre-exposure prophylaxis awareness and willingness to pay for pre-exposure prophylaxis among young adults in Western Kenya: results from a population-based survey. Int J STD AIDS. 2020;31:454–9. https://doi.org/10.1177/0956462420912141 .
doi: 10.1177/0956462420912141 pubmed: 32208816 pmcid: 7291793
Koss CA, Charlebois ED, Ayieko J, et al. Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study. Lancet HIV. 2020;7:e249–61. https://doi.org/10.1016/S2352-3018(19)30433-3 .
doi: 10.1016/S2352-3018(19)30433-3 pubmed: 32087152 pmcid: 7208546
Geldsetzer P, Bärnighausen K, Hettema A, et al. A stepped-wedge randomized trial and qualitative survey of HIV pre-exposure prophylaxis uptake in the Eswatini population. Sci Transl Med 2020;12. https://doi.org/10.1126/scitranslmed.aba4487 .
Hirschhorn LR, Brown RN, Friedman EE, et al. Black Cisgender Women’s PrEP Knowledge, Attitudes, Preferences, and Experience in Chicago. JAIDS J Acquir Immune Defic Syndr. 2020;84:497–507. https://doi.org/10.1097/QAI.0000000000002377 .
doi: 10.1097/QAI.0000000000002377 pubmed: 32692108
Ralph JA, Yeh C, Cowett A, Hirschhorn LR, Hammond C. Get PrEPPT (pre-exposure prophylaxis and pregnancy termination): an exploration of the values, attitudes and preferences regarding HIV and PrEP among women seeking abortion. BMJ Sex Reprod Health. 2020. https://doi.org/10.1136/bmjsrh-2020-200623 .
doi: 10.1136/bmjsrh-2020-200623 pubmed: 33122259
Dietrich JJ, Atujuna M, Tshabalala G, et al. A qualitative study to identify critical attributes and attribute-levels for a discrete choice experiment on oral pre-exposure prophylaxis (PrEP) delivery among young people in Cape Town and Johannesburg, South Africa. BMC Health Serv Res. 2021;21:17. https://doi.org/10.1186/s12913-020-05942-8 .
doi: 10.1186/s12913-020-05942-8 pubmed: 33407395 pmcid: 7788832
Underhill K, Morrow KM, Colleran CM, et al. Access to healthcare, HIV/STI testing, and preferred pre-exposure prophylaxis providers among men who have sex with men and men who engage in street-based sex work in the US. PLoS ONE. 2014;9:e112425. https://doi.org/10.1371/journal.pone.0112425 .
doi: 10.1371/journal.pone.0112425 pubmed: 25386746 pmcid: 4227700
Dubov A, Ogunbajo A, Altice FL, Fraenkel L. Optimizing access to PrEP based on MSM preferences: results of a discrete choice experiment. AIDS Care. 2019;31:545–53. https://doi.org/10.1080/09540121.2018.1557590 .
doi: 10.1080/09540121.2018.1557590 pubmed: 30554519
Lancaster KE, Lungu T, Bula A, et al. Preferences for Pre-exposure Prophylaxis Service Delivery Among Female Sex Workers in Malawi: A Discrete Choice Experiment. AIDS Behav. 2020;24:1294–303. https://doi.org/10.1007/s10461-019-02705-3 .
doi: 10.1007/s10461-019-02705-3 pubmed: 31720955 pmcid: 7995177
Roth AM, Tran NK, Felsher MA, et al. Integrating HIV pre-exposure prophylaxis with community-based syringe services for women who inject drugs: Results from the Project SHE demonstration study. J Acquir Immune Defic Syndr. 2020. https://doi.org/10.1097/QAI.0000000000002558 .
doi: 10.1097/QAI.0000000000002558 pubmed: 33136754
Eubanks A, Dembélé Keita B, Anoma C, et al. Reaching a Different Population of MSM in West Africa With the Integration of PrEP Into a Comprehensive Prevention Package (CohMSM-PrEP ANRS 12369—Expertise France). JAIDS J Acquir Immune Defic Syndr. 2020;85:292–301. https://doi.org/10.1097/QAI.0000000000002453 .
doi: 10.1097/QAI.0000000000002453 pubmed: 32732768
Eakle R, Bourne A, Mbogua J, Mutanha N, Rees H. Exploring acceptability of oral PrEP prior to implementation among female sex workers in South Africa. J Int AIDS Soc 2018;21. https://doi.org/10.1002/jia2.25081 .
Government of the Kingdom of Eswatini. “Swaziland HIV Incidence Measurement Survey 2 (SHIMS2) 2016–2017. Final report. ” Government of the Kingdom of Eswatini; 2019.
Justman J, Reed JB, Bicego G, et al. Swaziland HIV Incidence Measurement Survey (SHIMS): a prospective national cohort study. Lancet HIV. 2017;4(2):e83–92.
doi: 10.1016/S2352-3018(16)30190-4
Ministry of Health. Swaziland integrated HIV management guidelines. Government of the Kingdom of Eswatini; 2018.
WHO. Technical Update on Appropriate Medicines Options for Pre-Exposure Prophylaxis. 2017.
Mujugira A, Baeten JM, Hodges-Mameletzis I, Haberer JE. Lamivudine/Tenofovir Disoproxil Fumarate is an Appropriate PrEP Regimen. Drugs, 80(18), 1881–1888. https://doi.org/10.1007/s40265-020-01419-4 .
Schwarz G. Estimating the Dimension of a Model. The Annals of Statistics. 1978;6:461–4.
doi: 10.1214/aos/1176344136
Fop M, Smart KM, Murphy TB. Variable selection for latent class analysis with application to low back pain diagnosis. The Annals of Applied Statistics. 2017;11:2080–110. https://doi.org/10.1214/17-AOAS1061 .
doi: 10.1214/17-AOAS1061
Lumley T. Analysis of Complex Survey Samples. J Stat Softw. 2004;9:1–9. https://doi.org/10.18637/jss.v009.i08 .
doi: 10.18637/jss.v009.i08
Linzer D, Lewis J. poLCA: Polytomous variable Latent Class Analysis. 2014.
Fop M, Murphy TB. LCAvarsel. Variable Selection for Latent Class Analysis. 2018.
Kinuthia J, Pintye J, Abuna F, et al. Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. The Lancet HIV. 2020;7:e38–48. https://doi.org/10.1016/S2352-3018(19)30335-2 .
doi: 10.1016/S2352-3018(19)30335-2 pubmed: 31813837
Thomson KA, Hughes J, Baeten JM, et al. Increased Risk of HIV Acquisition Among Women Throughout Pregnancy and During the Postpartum Period: A Prospective Per-Coital-Act Analysis Among Women With HIV-Infected Partners. J Infect Dis. 2018;218:16–25. https://doi.org/10.1093/infdis/jiy113 .
doi: 10.1093/infdis/jiy113 pubmed: 29514254 pmcid: 5989601
Mlay R, Lugina H, Becker S. Couple counselling and testing for HIV at antenatal clinics: views from men, women and counsellors. AIDS Care. 2008;20(3):356–60.
doi: 10.1080/09540120701561304
Bärnighausen K, Matse S, Hughey AB, Hettema A, Bärnighausen TW, McMahon SA. “We know this will be hard at the beginning, but better in the long term”: understanding PrEP uptake in the general population in Eswatini. AIDS Care. 2020;32:267–73. https://doi.org/10.1080/09540121.2019.1653437 .
doi: 10.1080/09540121.2019.1653437 pubmed: 31437021

Auteurs

Maxime Inghels (M)

Lincoln International Institute for Rural Health, University of Lincoln, Brayford Pool, LN6 7TS, Lincoln, UK. maxime.inghels@gmail.com.
Centre Population et Développement, UMR 196 Paris Descartes - IRD), SageSud (ERL INSERM 1244), Institut de Recherche pour le Développement, Paris, France. maxime.inghels@gmail.com.

Hae-Young Kim (HY)

Africa Health Research Institute, KwaZulu-Natal, South Africa. hae-young.kim@nyulangone.org.
Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA. hae-young.kim@nyulangone.org.
KwaZulu-Natal Innovation and Sequencing Platform, KwaZulu-Natal, South Africa. hae-young.kim@nyulangone.org.

Frank Tanser (F)

Lincoln International Institute for Rural Health, University of Lincoln, Brayford Pool, LN6 7TS, Lincoln, UK. FTanser@lincoln.ac.uk.
Africa Health Research Institute, KwaZulu-Natal, South Africa. FTanser@lincoln.ac.uk.
School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa. FTanser@lincoln.ac.uk.
Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa. FTanser@lincoln.ac.uk.

Anita Hettema (A)

Clinton Health Access Initiative, H100, Mbabane, Eswatini, Swaziland. ahettema@clintonhealthaccess.org.

Shannon A McMahon (SA)

Heidelberg Institute of Global Health (HIGH), Heidelberg University, 69120, Heidelberg, Germany. mcmahon@uni-heidelberg.de.
Bloomberg School of Public Health, Johns Hopkins University, 21205, Baltimore, MD, USA. mcmahon@uni-heidelberg.de.

Catherine E Oldenburg (CE)

Department of Ophthalmology, University of California, San Francisco, 94115, San Francisco, CA, USA. catherine.oldenburg@ucsf.edu.
Francis I. Proctor Foundation, University of California, San Francisco, 94122, San Francisco, CA, USA. catherine.oldenburg@ucsf.edu.
Department of Epidemiology and Biostatistics, University of California, 94158, San Francisco, CA, USA. catherine.oldenburg@ucsf.edu.

Sindy Matse (S)

Eswatini Ministry of Health, Mbabane, Eswatini, Swaziland. matsesindy@gmail.com.

Stefan Kohler (S)

Heidelberg Institute of Global Health (HIGH), Heidelberg University, 69120, Heidelberg, Germany. stefan.kohler@uni-heidelberg.de.
Institute of Social Medicine, Epidemiology and Health Economics, Charité?Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. stefan.kohler@uni-heidelberg.de.

Pascal Geldsetzer (P)

Division of Primary Care and Population Health, Department of Medicine, Stanford University, Stanford, CA, United States. pgeldsetzer@gmail.com.

Till Bärnighausen (T)

Africa Health Research Institute, KwaZulu-Natal, South Africa. till.baernighausen@uni-heidelberg.de.
Heidelberg Institute of Global Health (HIGH), Heidelberg University, 69120, Heidelberg, Germany. till.baernighausen@uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH